• Users Online: 298
  • Print this page
  • Email this page


 
 
Table of Contents
LETTER TO EDITOR
Year : 2020  |  Volume : 22  |  Issue : 1  |  Page : 71

Proadrenomedullin determining clinical severity and analyzing prognostic value for pneumonia


1 Department of Pulmonology, Sultan Abdulhamid Han Research Hospital, Istanbul, Turkey
2 Department of Pulmonology Baskent University, Istanbul Education and Research Hospital, Istanbul, Turkey

Date of Submission08-Nov-2019
Date of Acceptance08-Nov-2019
Date of Web Publication30-Apr-2020

Correspondence Address:
Dr. Dilaver Tas
Department of Pulmonology, Baskent University, Istanbul Education and Research Hospital, Istanbul
Turkey
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ejop.ejop_94_19

Rights and Permissions

How to cite this article:
Demirsoy S, Okutan O, Kartaloglu Z, Tas D, Ayten O, Canoglu K. Proadrenomedullin determining clinical severity and analyzing prognostic value for pneumonia. Eurasian J Pulmonol 2020;22:71

How to cite this URL:
Demirsoy S, Okutan O, Kartaloglu Z, Tas D, Ayten O, Canoglu K. Proadrenomedullin determining clinical severity and analyzing prognostic value for pneumonia. Eurasian J Pulmonol [serial online] 2020 [cited 2020 Oct 24];22:71. Available from: https://www.eurasianjpulmonol.com/text.asp?2020/22/1/71/283637



Sir,

Thanks for your interest. As you stated, proadrenomedullin (proADM) is an interesting biomarker, and many researchers studied its value for various physiologic and also pathologic conditions. Many noninfectious situations alter proADM levels, but Kutz et al. encourage that “reinforce the concept of using biomarkers in algorithms with widely separated cutoffs despite statistically significant associations of some preanalytic factors and biomarker levels.”[1] Our primary aim was to determine and compare proADM with clinical severity scores for pneumonia and validate its value with regard to that of previous studies, at a prospective work. We found no statistical superiority in favor of proADM. In a meta-analysis, Liu et al. concluded that proADM sensitivity and specificity – to predict mortality in community-acquired pneumonia – were 0.74 (95% confidence interval [CI]: 0.67–0.79) and 0.73 (95% CI: 0.70–0.77), respectively.[2] As a result, there is no sufficient evidence yet to rely on only proADM for pneumonia severity instead of clinical scores as its value was altered by multiple conditions. Eventually combining with other biomarkers and scores is much more promising.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
  References Top

1.
Kutz A, Grolimund E, Christ-Crain M, Thomann R, Falconnier C, Hoess C, et al. Pre-analytic factors and initial biomarker levels in community-acquired pneumonia patients. BMC Anesthesiol 2014;14:102.  Back to cited text no. 1
    
2.
Liu D, Xie L, Zhao H, Liu X, Cao J. Prognostic value of mid-regional pro-adrenomedullin (MR-proADM) in patients with community-acquired pneumonia: A systematic review and meta-analysis. BMC Infect Dis 2016;16:232.  Back to cited text no. 2
    




 

Top
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
References

 Article Access Statistics
    Viewed292    
    Printed21    
    Emailed0    
    PDF Downloaded59    
    Comments [Add]    

Recommend this journal